5 results about "Deferasirox" patented technology

Metal chelation compounds and associated coordination complexes are provided. In one aspect, this disclosure provides for a metal chelation compound, the compound having the general structure: D-L-T, wherein D is deferasirox or a derivative thereof, T is triapine or a derivative thereof, and L is a linking group and is a bond, C1-C10 alkyl, C2-C10 alkenyl, or —(C0-C3 alkyl)-R—(C0-C3 alkyl)-, wherein R is aryl, cycloalkyl, or polyethylene glycol.

The invention relates to deferasirox as a human xanthine oxidase inhibitor and application thereof. Specifically, the invention provides application of deferasirox or pharmaceutically acceptable salts, esters, isomers, solvates or prodrugs thereof in preparation of drugs for treating or preventing diseases or symptoms benefited from reduction or inhibition of xanthine oxidase expression or activity, and application of deferasirox or pharmaceutically acceptable salts, esters, isomers, solvates or prodrugs thereof in preparation of drugs for treating or preventing diseases or symptoms benefited from reduction or inhibition of xanthine oxidase expression or activity. Or application in preparation of drugs for treating or preventing diseases or symptoms benefited from inhibition of uric acid production and / or reduction of uric acid content.

The invention relates to the technical field of medicines, in particular to application of a pharmaceutical composition in preparation of a medicine for treating thalassemia. The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from the following components in parts by mass: 2 to 5 parts of pravastatin sodium, 1 to 2 parts of roteciterp, 7 to 11 parts of deferasirox, 7 to 11 parts of morroniside and 30 to 40 parts of phellinus igniarius general flavone extract. The pharmaceutical composition provided by the invention shows multiple clinical beneficial effects in treatment of thalassemia. In the aspect of curative effect, the composition can significantly increase the number of peripheral red blood cells, the content of hemoglobin and the hematocrit of the peripheral blood of a patient and effectively reduce the variable coefficient of the volume of the red blood cells, which indicates that the composition not only can improve the anemia state, but also can improve the stability of the quality of the red blood cells. Besides, the traditional Chinese medicine composition can obviously relieve spleen enlargement and iron overload degree and reduce the iron deposition level of the liver and the spleen, so that the traditional Chinese medicine composition has a positive effect in the aspects of relieving hemolysis related complications and organ iron toxicity.

This invention provides a method for synthesizing deferasirox. The method involves reacting starting material A with hydrochloric acid-ethanol solution in solvent a to generate intermediate B; intermediate B reacts with salicylyl chloride and pyridine in solvent b to generate intermediate C; and intermediate C reacts with p-hydrazide benzoate in solvent c to generate deferasirox. This method is simple to operate, has mild reaction conditions, high yield, low cost, is environmentally friendly, and is suitable for large-scale industrial production of deferasirox.